Compare Chemed Corporation (CHE) vs Fresenius Medical Care AG & Co. KGaA (FMS) Stock

Fresenius Medical Care AG & Co. KGaA (FMS) offers the better valuation at 11.8x trailing P/E (9.9x forward), making it the more compelling value choice. Analysts rate Chemed Corporation (CHE) a "Hold" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Fresenius Medical Care AG & Co. KGaA (FMS) is the cheapest at 11.8x versus Chemed Corporation at 22.3x. On forward P/E, Fresenius Medical Care AG & Co. KGaA is actually cheaper at 9.9x.

Over the past 5 years, Chemed Corporation (CHE) delivered a total return of -6.1%, compared to -22.8% for Fresenius Medical Care AG & Co. KGaA (FMS). A $10,000 investment in CHE five years ago would be worth approximately $9K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CHE returned +230.4% versus FMS's -28.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Chemed Corporation (CHE) is the lower-risk stock at 0.27β versus Fresenius Medical Care AG & Co. KGaA's 0.40β — meaning FMS is approximately 48% more volatile than CHE relative to the S&P 500. On balance sheet safety, Chemed Corporation (CHE) carries a lower debt/equity ratio of 15% versus 76% for Fresenius Medical Care AG & Co. KGaA — giving it more financial flexibility in a downturn.

Chemed Corporation (CHE) is the more profitable company, earning 10.5% net margin versus 5.0% for Fresenius Medical Care AG & Co. KGaA — meaning it keeps 10.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CHE leads at 13.4% versus 9.3% for FMS. At the gross margin level — before operating expenses — FMS leads at 25.6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Fresenius Medical Care AG & Co. KGaA (FMS) trades at 9.9x forward P/E versus 16.8x for Chemed Corporation — 6.9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FMS: 19.4% to $28.00.

In this comparison, CHE (0.5% yield) pays a dividend. FMS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Chemed Corporation (CHE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.27), 0.5% yield, +230.4% 10Y return). Both have compounded well over 10 years (CHE: +230.4%, FMS: -28.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: CHE is a small-cap quality compounder stock; FMS is a mid-cap deep-value stock. CHE pays a dividend while FMS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.